Vanguard Global Advisers
AARD

Vanguard Global Advisers’s Aardvark Therapeutics AARD Stock Holding History

Vanguard Global Advisers’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.9K Hold
5,893
– – ﹤0.01% 3195
2026
Q1 		$22.2K Buy
+5,893
New +$61.1K ﹤0.01% 3273

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.23B AUM 74.49% 1-Year Est. Return

Vanguard Global Advisers's AARD Position: Q2 2026 in Review

Vanguard Global Advisers held its Aardvark Therapeutics (AARD) position steady in Q2 2026 at 5,893 shares worth $33.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3195.

Vanguard Global Advisers first reported a position in AARD in Q1 2026 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Vanguard Global Advisers held 5,893 shares of Aardvark Therapeutics worth $33.9K as of Q2 2026.
  • Vanguard Global Advisers left its Aardvark Therapeutics share count unchanged in Q2 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3195 holding.
  • Vanguard Global Advisers first reported a position in Aardvark Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.